ALX ONCOLOGY HOLDINGS INC — Form 8-K

ALX Oncology refinanced $10M debt with HSBC Ventures USA Inc., securing access to an additional $20M through June 2028 from a total $50M facility (with $10M uncommitted), replacing prior Oxford Finance/SVB agreement and lowering cost of capital. Cash, cash equivalents, and investments totaled $153.4M as of June 30, 2026, sufficient to fund operations through H1 2028. Q2 2026 GAAP net loss was $18.0M ($0.13/share) vs. $25.9M ($0.49/share) prior year; non-GAAP net loss $14.3M vs. $20.6M prior year. Leadership strengthened with Scott Garland appointed Chairman and Michael Listgarten as General Counsel (June 2026). ASPEN-09-Breast Phase 2 trial (80 patients, evorpacept + trastuzumab) on track for mid-2027 topline; ALX2004 Phase 1 dose escalation advancing toward 2H 2026 safety data.